Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to evaluate the efficacy and toxicity of oxaliplatin, leucovorin,and 5-fluorouracil (FOLFOX-4) chemotherapy in heavily pretreated patients with recurrent epithelial ovarian cancer (EOC). Materials and Methods Clinical data were reviewed in 28 patients who received FOLFOX-4 as more than the second-line chemotherapy, consisting of 85 mg/m2 of oxaliplatin as a 2-hour infusion,200 mg/m2 of leucovorin as a 2-hour infusion, and bolus 400 mg/m2 on day 1,followed by a 22-hour infusion of 600 mg/m2 of 5-fluorouracil for two consecutive days every three weeks. In addition, its efficacy and toxicity were compared with those reported in in three previous relevant studies. Results A total of 128 cycles of FOLFOX-4 were administered with the median number of five cycles (range, 1 to 10 cycles). In nine patients with measurable disease, complete response (CR) and partial response (PR) were observed in 0 (0%) and two (22.2%)patients, whereas in 19 patients with non-measurable disease, CR and PR were observed in 0 (0%) and five (26.3%) patients. Among all patients, grade 3 anemia,neutropenia, and thrombocytopenia were observed in two (7.1%), three (10.7%), and one (3.6%) patient, and grade 3 fatigue, nausea and vomiting, and peripheral neuropathy were observed in one (3.6%), two (7.1%), and three (10.7%) patients. In addition, median values of time to progressive disease and chemotherapy-specific survival were three months (range, 0 to 10 months) and nine months (range, 4 to 24months). Conclusion FOLFOX-4 is feasible as salvage chemotherapy with acceptable toxicity for heavily pretreated patients with recurrent EOC.
Abstract
Purpose The purpose of this study is to evaluate the efficacy and toxicity of oxaliplatin, leucovorin,and 5-fluorouracil (FOLFOX-4) chemotherapy in heavily pretreated patients with recurrent epithelial ovarian cancer (EOC). Materials and Methods Clinical data were reviewed in 28 patients who received FOLFOX-4 as more than the second-line chemotherapy, consisting of 85 mg/m2 of oxaliplatin as a 2-hour infusion,200 mg/m2 of leucovorin as a 2-hour infusion, and bolus 400 mg/m2 on day 1,followed by a 22-hour infusion of 600 mg/m2 of 5-fluorouracil for two consecutive days every three weeks. In addition, its efficacy and toxicity were compared with those reported in in three previous relevant studies. Results A total of 128 cycles of FOLFOX-4 were administered with the median number of five cycles (range, 1 to 10 cycles). In nine patients with measurable disease, complete response (CR) and partial response (PR) were observed in 0 (0%) and two (22.2%)patients, whereas in 19 patients with non-measurable disease, CR and PR were observed in 0 (0%) and five (26.3%) patients. Among all patients, grade 3 anemia,neutropenia, and thrombocytopenia were observed in two (7.1%), three (10.7%), and one (3.6%) patient, and grade 3 fatigue, nausea and vomiting, and peripheral neuropathy were observed in one (3.6%), two (7.1%), and three (10.7%) patients. In addition, median values of time to progressive disease and chemotherapy-specific survival were three months (range, 0 to 10 months) and nine months (range, 4 to 24months). Conclusion FOLFOX-4 is feasible as salvage chemotherapy with acceptable toxicity for heavily pretreated patients with recurrent EOC.
참고문헌 (21)
- Dong Hoon Suh, "Major clinical research advances in gynecologic cancer in 2011", Journal of Gynecologic Oncology, 23(1), pp.53~64 (2012), 대한부인종양학회
- Ozols RF, "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study", J Clin Oncol, 21, pp.3194~3200 (2003)
- Markman M., "Optimal management of recurrent ovarian cancer", Int J Gynecol Cancer, 19(Suppl 2), pp.S40~S43 (2009)
- 김윤환, "Recent advances in the biomarkers for epithelial ovarian cancer", Journal of Gynecologic Oncology, 22(4), pp.219~221 (2011), 대한부인종양학회
- Raymond E, "Oxaliplatin: a review of preclinical and clinical studies", Ann Oncol, 9, pp.1053~1071 (1998)
- Rixe O, "Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel", Biochem Pharmacol, 52, pp.1855~1865 (1996)
- Prefontaine M, "Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin", Gynecol Oncol, 61, pp.249~252 (1996)
- Look KY, "A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study", Am J Clin Oncol, 18, pp.19~22 (1995)
- Raymond E, "Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers", Anticancer Drugs, 8, pp.876~885 (1997)
- Goldberg RM, "A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer", J Clin Oncol, 22, pp.23~30 (2004)
- Pectasides D, "Oxaliplatin plus high-dose leucovorin and 5- fluorouracil in pretreated advanced breast cancer: a phase II study", Ann Oncol, 14, pp.537~542 (2003)
- Sundar S, "Phase II trial of oxaliplatin and 5-fluorouracil", leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy, 2004, pp.94, 502~508
- Pectasides D, "Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study", Gynecol Oncol, 95, pp.165~172 (2004)
- Rosa DD, "Oxaliplatin", 5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma, 2008, pp.278, 457~462
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Rustin GJ, "Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125", J Clin Oncol, 14, pp.1545~1551 (1996)
- "Common terminology criteria for adverse events" (2003)[URL]
- Mathe G, "Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum", Biomed Pharmacother, 43, pp.237~250 (1989)
- Dieras V, "Multicentre phase II study of oxaliplatin as a single-agent in cisplatin", carboplatin +, Ann Oncol, pp.2002, 13[DOI]
- Chollet P, "Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer", Ann Oncol, 7, pp.1065~1070 (1996)
- Morgan RJ Jr, "Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol", Gynecol Oncol, 58, pp.79~85 (1995)